Biotech Breakthroughs — 2026-05-15

Top Breakthroughs This Week

1. Bizengri Becomes First Drug Approved for NRG1-Fusion Cholangiocarcinoma Under Priority Voucher Program

• Company / Institution: FDA / undisclosed sponsor (National Priority Voucher Pilot Program)
• What happened: The FDA granted its seventh approval under the National Priority Voucher Pilot Program for Bizengri, making it the first drug ever approved for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.
• Indication / Target: Advanced/metastatic cholangiocarcinoma (bile duct cancer) with NRG1 gene fusion; heavily pretreated adult patients
• Why it matters: NRG1 gene fusions represent a rare but actionable oncogenic driver across multiple tumor types, and this approval establishes the first targeted therapy for this molecularly defined cholangiocarcinoma population. The Priority Voucher Program was designed to accelerate treatments for rare and neglected diseases, and this seventh approval signals the program's growing clinical impact for patients with limited options.

4 sources

fda.gov

Novel Drug Approvals for 2026 | FDA

fda.gov

Novel Drug Approvals for 2025 | FDA

fda.gov

FDA Grants Seventh Approval under the National Priority Voucher Pilot Program | FDA

fda.gov

2026 Biological Approvals | FDA

2. Aardvark Therapeutics Hit With FDA Clinical Hold After HERO and OLE Trials

• Company / Institution: Aardvark Therapeutics, Inc. (Nasdaq: AARD)
• What happened: On May 14, 2026, Aardvark Therapeutics announced it plans to unblind data from its HERO and OLE studies following an FDA-imposed clinical hold on its lead obesity drug program. The company stated it will use the unblinded data to determine the path forward for the program.
• Indication / Target: Obesity; the company's lead investigational compound was in clinical-stage evaluation
• Why it matters: A clinical hold is a significant setback that halts patient enrollment and dosing, casting uncertainty over Aardvark's obesity pipeline at a time when the GLP-1 and weight-loss drug space is intensely competitive. The decision to unblind trial data suggests the company is reassessing both the safety profile and the strategic direction of the program, with near-term pipeline and investor implications.

3. Kelun-Biotech Receives Chinese IND Approval for PD-1 × VEGF Bispecific Antibody SKB118

• Company / Institution: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK)
• What happened: Kelun-Biotech announced receipt of Investigational New Drug (IND) approval from China's Center for Drug Evaluation (CDE) for SKB118, a novel PD-1 × VEGF bispecific antibody, enabling the company to proceed to clinical trials.
• Indication / Target: Oncology — bispecific antibody simultaneously targeting PD-1 (immune checkpoint) and VEGF (tumor angiogenesis); broad solid tumor potential
• Why it matters: The PD-1 × VEGF bispecific class has garnered enormous attention following Ivonescimab's strong data readouts in China, and Kelun-Biotech's SKB118 adds competitive momentum to this rapidly crowding space. With China's CDE approval in hand, this positions Kelun-Biotech to generate clinical proof-of-concept data for a mechanism that combines immune checkpoint blockade with anti-angiogenic activity — a potentially differentiated approach relative to PD-1 monotherapy.

1 sources

prnewswire.com

prnewswire.com

Regulatory Roundup

• Bizengri (undisclosed sponsor) — FDA granted approval under the National Priority Voucher Pilot Program for advanced cholangiocarcinoma with NRG1 gene fusion; this is the seventh approval under this pilot, establishing the first-ever targeted therapy for this rare genomic subset of bile duct cancer.

• Aardvark Therapeutics (AARD) — FDA issued a clinical hold on the company's obesity drug program (HERO and OLE trials); Aardvark announced on May 14, 2026 it will unblind trial data to inform next steps, creating significant near-term uncertainty for the program.

• Multiple drugs across cardiology, COVID-19, gout, and thyroid eye disease — June 2026 PDUFA dates are approaching for treatments across these indications including gout, nicotine dependence, severe hypertriglyceridemia, and thyroid eye disease, according to published FDA action date trackers; these upcoming decisions represent the next wave of near-term regulatory catalysts.

Therapeutic Modality Watch

Gene & Cell Therapy

• The FDA's previously announced "plausible mechanism pathway" for bespoke gene-editing treatments — a framework enabling one-time gene-editing cures for rare diseases — continues to generate industry activity in 2026, with expectations of a flood of applications. The pathway, unveiled in February 2026, has raised both excitement and ethical scrutiny regarding the pace of access to experimental CRISPR-based treatments.

• Academic CRISPR-on-demand programs at Penn-CHOP (metabolic diseases), University of Wisconsin (congenital blindness), and IGI-UCSF (inborn errors of immunity) are advancing toward umbrella trial structures in 2026, representing the leading edge of bespoke gene medicine.

• Oricell Therapeutics, a Chinese cell therapy company, raised $110 million in a pre-IPO round (announced April 10, 2026), with investors including Vivo Capital and Qiming Venture Partners, positioning the company to seek a public listing after previously closing a $70M Series C1 in January 2026.

Small Molecules & Biologics

• Kelun-Biotech's SKB118 PD-1 × VEGF bispecific antibody received Chinese IND approval this week, entering an increasingly crowded but scientifically validated category following strong clinical signals from earlier-generation bispecifics in this class.

• Bizengri (NRG1-fusion cholangiocarcinoma) received FDA approval this week under the National Priority Voucher Program — the first approval specifically for this rare oncogenic driver in bile duct cancer.

• June 2026 FDA PDUFA decisions are pending for drugs targeting COVID-19, gout, severe hypertriglyceridemia, nicotine dependence, and thyroid eye disease — a diverse portfolio of small molecule and biologic candidates across multiple therapeutic areas.

Platform & Discovery Tech

• The FDA's real-time clinical trials pilot program — involving AstraZeneca and Amgen cancer drugs monitored in real time to shorten intervals between trial phases — continues to generate data, with the agency testing whether continuous monitoring can compress development timelines.

• The type 1 diabetes (T1D) cure pipeline in 2026 encompasses multiple curative approaches including encapsulated cell therapies, antigen-specific immune tolerance strategies, and stem cell-derived beta cell transplants, with several programs in active clinical evaluation according to a comprehensive 2026 update.

Business & Pipeline Moves

• Biotech IPO market, Q1 2026 — Six biotech companies priced IPOs in Q1 2026, banking a median of $287.5 million each — a figure far surpassing comparable timeframes in prior years, signaling renewed investor appetite for large, well-capitalized public offerings despite a slower-than-pandemic-era pace. Industry analysts predict 30–35 biotech IPOs in 2026 if market conditions hold.

• Seaport and Hemab — Two biotechs raised a combined $556 million in IPO proceeds in the most recent wave of public offerings, with the broader 2026 sector on track to complete approximately two dozen offerings for the year.

• Oricell Therapeutics (pre-IPO) — The Chinese cell therapy company completed a $110 million pre-IPO round on April 10, 2026, with backing from Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and others; the company is pursuing a public listing following this final private funding round.

• Aktis Oncology — Kicked off 2026's biotech IPO calendar by raising $318 million in January 2026, having previously accumulated $346 million in private backing from MPM BioImpact, Vida Ventures, and RA Capital, with a focus on radiopharmaceuticals for cancer.

Analyst Take

• Dominant theme this week: Precision oncology remains the defining theme, anchored by the FDA's approval of Bizengri for NRG1-fusion cholangiocarcinoma. This reflects a broader industry migration toward molecularly defined patient populations and rare genomic subsets as viable regulatory and commercial targets, even in traditionally underserved cancers.

• Momentum shift: Bispecific antibodies — particularly PD-1 × VEGF combinations — are gaining momentum as a preferred next-generation oncology modality, with Kelun-Biotech's SKB118 IND approval this week adding to a growing number of programs. The class has effectively shifted from experimental to validated, and the race to differentiate on schedule, combination strategy, and tumor type is now central to competitive positioning.

• Risk signals: Aardvark Therapeutics' FDA clinical hold on its obesity program serves as a reminder that even the hottest therapeutic area (weight loss/metabolic disease) is not immune to safety or regulatory setbacks. With the GLP-1 market intensely competitive, any delay meaningfully erodes a company's ability to carve out market share. Investors should watch for the unblinded HERO and OLE data readout and any FDA communication on the basis for the hold.

What to Watch Next Week

• Aardvark Therapeutics HERO/OLE data unblinding: Following the May 14 clinical hold announcement, the market is awaiting disclosure of unblinded trial data and FDA communication about the grounds for the hold — which could determine whether the program continues, pivots, or is discontinued. Timing is not confirmed but investor pressure makes this an imminent catalyst.

• June 2026 FDA PDUFA dates: Multiple PDUFA action dates are approaching for drugs targeting COVID-19, gout, severe hypertriglyceridemia, nicotine dependence, and thyroid eye disease — several of which will be decided in early-to-mid June. Watch for FDA decisions beginning in late May through June 15.

• Biotech IPO pipeline: With the sector on pace for 20–24 IPOs in 2026 and two dozen already in discussion, additional IPO pricings are expected in the coming weeks. Monitor the Oricell Therapeutics public filing timeline and any new S-1 registrations from companies in the cell therapy and radiopharmaceutical spaces.

Reader Action Items

• For investors: Monitor Aardvark Therapeutics (AARD) closely — the FDA clinical hold catalyst is binary: if the unblinded HERO/OLE data support safety and efficacy, a path forward exists; if not, the stock faces material downside. Also watch for additional biotech IPO pricings as a market sentiment barometer.

• For operators & scientists: Read the full FDA announcement on the National Priority Voucher Pilot Program approval of Bizengri for NRG1-fusion cholangiocarcinoma — the regulatory precedent for molecularly defined rare oncology indications could inform your own IND/NDA strategy.

• For patient advocates: The Bizengri FDA approval is the most immediately impactful development for patients this week — the first therapy specifically approved for cholangiocarcinoma patients whose tumors harbor an NRG1 gene fusion, a population with very limited prior treatment options. Engage with bile duct cancer advocacy groups to ensure eligible patients are being tested for NRG1 fusion status.